Endpoints News 5 may 2026 Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma
Moderna 5 may 2026 Boston biotech firms back new effort to preserve U.S. edge in life sciences - The Business Journals
Revvity 5 may 2026 Revvity Outperforms in Q1 2026 Driven by Pharma Rebound and Strategic Portfolio Shifts - Lab Manager
FierceBiotech 5 may 2026 Olympus, EndoRobotics in distribution pact for robot-assisted endoscopic tech